Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.41 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | IGF2R | P11717 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16377897 | 1.00 | LGALS8 (0.41) | LGALS8LGALS3LGALS4MAPK1MMP1 | |
| SCHEMBL23652153 | 1.00 | LGALS8 (0.41) | LGALS8LGALS3LGALS4MAPK1MMP1 | |
| SCHEMBL13944872 | 0.85 | LGALS8 (0.40) | LGALS8LGALS3LGALS4MAPK1MMP1 | |
| SCHEMBL22328414 | 0.85 | LGALS8 (0.40) | LGALS8LGALS3LGALS4MAPK1MMP1 | |
| SCHEMBL16658408 | 0.85 | LGALS8 (0.40) | LGALS8LGALS3LGALS4MAPK1MMP1 | |
| SCHEMBL15927382 | 0.85 | MAPK1 (0.37) | LGALS8LGALS3LGALS4MAPK1CA12 | |
| SCHEMBL13944870 | 0.83 | PYGB (0.39) | LGALS8CA12CA1CA2CA9 | |
| SCHEMBL16658586 | 0.82 | ACHE (0.31) | — | |
| SCHEMBL23652112 | 0.77 | GAA (0.40) | CA12CA1CA2CA9 | |
| SCHEMBL13945298 | 0.77 | GAA (0.40) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240065990-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH INC (CA) | 2024-02-29 | — | — | US | disclosed |
| US-20210386693-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2021-12-16 | — | — | US | disclosed |
| EP-3851447-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BHI Limited Partnership (CA) | 2021-07-21 | — | — | EP | disclosed |
| US-11020360-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BELLUS HEALTH INC. (CA) | 2021-06-01 | — | — | US | disclosed |
| US-10857109-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | Bellus Health, Inc. (CA) | 2020-12-08 | — | — | US | disclosed |
| US-20200253897-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2020-08-13 | — | — | US | disclosed |
| US-10238611-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BELLUS HEALTH INC. (CA) | 2019-03-26 | — | — | US | disclosed |
| US-20170095430-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH INC. (CA) | 2017-04-06 | — | — | US | disclosed |
| US-9499480-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BHI LIMITED PARTNERSHIP (CA) | 2016-11-22 | — | — | US | disclosed |
| EP-2862581-A2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BHI Limited Partnership (CA) | 2015-04-22 | — | — | EP | disclosed |
| US-20140220122-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BHI LIMITED PARTNERSHIP (CA) | 2014-08-07 | — | — | US | disclosed |
| US-8748656-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BHI LIMITED PARTNERSHIP (CA) | 2014-06-10 | — | — | US | disclosed |
| US-8748656-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BHI LIMITED PARTNERSHIP (CA) | 2014-06-10 | — | — | US | disclosed |
| WO-2009019534-A2 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20080146642-A1 | Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease | BELLUS HEALTH INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-20080146642-A1 | Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease | BELLUS HEALTH INC. (CA) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170095430-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | LGALS8 2190/4885LGALS3 496/4885LGALS4 1970/4885 |
| US-20240065990-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | LGALS8 2126/4885LGALS3 458/4885LGALS4 1832/4885 |
| US-11020360-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | APP, PSEN1, DNPEP | LGALS8 2313/4885LGALS3 552/4885LGALS4 2028/4885 |
| US-10857109-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | APP, PSEN1, DNPEP | LGALS8 2313/4885LGALS3 552/4885LGALS4 2028/4885 |
| US-20210386693-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | LGALS8 2190/4885LGALS3 496/4885LGALS4 1970/4885 |
| US-20200253897-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | LGALS8 2190/4885LGALS3 496/4885LGALS4 1970/4885 |
| US-20080146642-A1 | Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease | DNPEP, DAO, APP | LGALS8 4409/4885LGALS3 3031/4885LGALS4 4323/4885 |
| US-20140220122-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | LGALS8 2190/4885LGALS3 496/4885LGALS4 1970/4885 |
| US-10238611-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | APP, PSEN1, DNPEP | LGALS8 2313/4885LGALS3 552/4885LGALS4 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.